Live feed08:00:00·338dPRReleasevia QuantisnowOpus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ConditionsByQuantisnow·Wall Street's wire, on your screen.IRD· Opus Genetics Inc.Health Care
